4.7 Article

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children

期刊

CLINICAL INFECTIOUS DISEASES
卷 52, 期 3, 页码 E18-E55

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciq146

关键词

-

资金

  1. Cubist
  2. Ortho-McNeil
  3. Pfizer
  4. Theravance
  5. Targanta
  6. Astellas
  7. AdvanDx
  8. Clorox
  9. Sanofi Pasteur
  10. Sage
  11. GeneOhm
  12. Cubist Pharmaceuticals
  13. Merck
  14. Wyeth
  15. Johnson Johnson
  16. Sanofi-Aventis
  17. Vicuron Pharmaceuticals
  18. Wyeth-Ayerst
  19. Theravance/Astellas

向作者/读者索取更多资源

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据